13 / 24
Second-line therapy after nab-paclitaxel plus gemcitabine or gemcitabine for patients
with metastatic pancreatic cancer (exploratory analysis of MPACT trial)
Chiorean et al,
Br J Cancer 2016
Total OS in patients who received 2L
Second line OS
•
The majority of 2L contained 5FU (77%)
•
The total OS in the subgroup of patients who received 5-FU was longer for those who received
Gem+Nab (13.5 m vs 9.5 m)
•
These results showed that a 5-FU containing treatment after 1L nab+gem or gem may be an active
treatment sequence with favorable clinical benefit.